Gilead Sciences (GILD) News Today

Capital International Inc. CA raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 24.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 234,917 shares of the biopharmaceutical company's stock after purchasing an additional 46,848 shares duri

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) was the recipient of some unusual options trading on Friday. Traders bought 45,351 put options on the stock. This is an increase of 110% compared to the average daily volume of 21,601 put options.

National Bank of Canada FI lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 30.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 811,375 shares of the biopharmaceutical company's stock a

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2024 earnings per share estimates for shares of Gilead Sciences in a report released on Monday, July 22nd. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical c

UniSuper Management Pty Ltd increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 195,489 shares of the biopharmaceutical company's stock after buying an additional

Edgestream Partners L.P. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 447.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,973 shares of the biopharmaceutical company

Jupiter Asset Management Ltd. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 92.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,077 shares of the biopharmaceutical

M&G Plc bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 97,008 shares of the biopharmaceutical company's stoc

Trillium Asset Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 25.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 164,129 share

Gilead Sciences (NASDAQ:GILD) Stock Price Down 1.4%

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 19.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,571,510 shares of the biopharmaceutical company's stock a

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) has been given an average rating of "Hold" by the nineteen analysts that are presently covering the stock, Marketbeat Ratings reports. Twelve investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to t

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) was the target of a significant growth in short interest in June. As of June 30th, there was short interest totalling 23,000,000 shares, a growth of 22.3% from the June 15th total of 18,810,000 shares. Based on an average daily volume of 7,530,000 shares, the short-interest ratio is currently 3.1 days. Approximately 1.9% of the company's stock are sold short.

Russell Investments Group Ltd. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,026,980 shares of the biopharmaceutical compan

Gilead Sciences (NASDAQ:GILD) Trading 1.7% Higher

Meeder Asset Management Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 19.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 75,308 shares of the biopharmaceutical

Gilead Sciences (NASDAQ:GILD) Shares Up 1.2%

IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather

SG Americas Securities LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 51.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 154,992 shares of the biopharmaceutical company's stock afte

Oppenheimer Asset Management Inc. lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 152,076 shares of the biopharmaceutical company's stock after selling 25

LSV Asset Management lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,676,749 shares of the biopharmaceutical company's stock afte

Gilead Sciences (NASDAQ:GILD) Shares Up 0.3%

Gilead Sciences (NASDAQ:GILD) Trading 0.7% Higher

Mediolanum International Funds Ltd acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 62,892 shares of the biopharmaceutical company

Gilead Sciences (NASDAQ:GILD) Trading Up 1.4%

Central Pacific Bank Trust Division bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 14,083 shares of the biopharmaceuti

Gilead Sciences (NASDAQ:GILD) Stock Price Down 0.6%

Gilead Sciences (NASDAQ:GILD) Shares Up 1.8%

Raymond James raised shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $93.00 price target on the stock in a research report on Monday.